Evaluation of prostaglandin D2 (PGD2) as an anticoagulative agent for haemodialysis in comparison with prostaglandin E1 (PGE1).
Prostaglandin D2 (PGD2), a potent antiplatelet agent, was evaluated as an antithrombotic agent for haemodialysis in comparison with prostaglandin E1 (PGE1) and prostaglandin I2 (PGI2). When antiplatelet action was evaluated, taking the degree of associated hypotension into consideration, PGD2 was found to be superior to PGE1 and PGI2 as the latter two had the negative effect of inducing hypotension, while PGD2 had a less hypotensive effect. The suppression of the platelet function by PGD2 was observed to have only a slight influence on platelet function in systemic blood.
D000527:Alprostadil; D011464:Epoprostenol / Q000494:pharmacology; D005343:Fibrinolytic Agents / Q000494:pharmacology / Q000627:therapeutic use*; D006801:Humans; D007676:Kidney Failure, Chronic / Q000097:blood* / Q000628:therapy; D010974:Platelet Aggregation / Q000187:drug effects*; D015230:Prostaglandin D2; D011453:Prostaglandins / Q000627:therapeutic use*; D011457:Prostaglandins D / Q000494:pharmacology / Q000627:therapeutic use*; D011458:Prostaglandins E / Q000494:pharmacology / Q000627:therapeutic use*; D006435:Renal Dialysis
D005343:Fibrinolytic Agents; D011453:Prostaglandins; D011457:Prostaglandins D; D011458:Prostaglandins E; D011464:Epoprostenol; D000527:Alprostadil; D015230:Prostaglandin D2